1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19: 716?723
2. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxy daunorubicin in patients with advanced cancer. Cancer Res 43: 6096?6101
3. Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F (1982) Pharmacokinetic studies of 4?-epidoxorubicin in cancer patients with normal and impaired renal functions and with hepatic metastases. Cancer Treat Rep 66: 1819?1824
4. Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, Pannuti F (1985) Epirubicin plasma and blood pharmacokinetics after single IV bolus in advanced cancer patients. Drugs Expt Clin Res 11: 285?294
5. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother Pharmacol 21: 221?228